~~<i id='CE8AD20A75'><strike id='CE8AD20A75'><tt id='CE8AD20A75'><pre id='CE8AD20A75'></pre></tt></strike></i>~~

Home» Wikipedia» Wikipedia

Wikipedia

author：leisure time 2025-09-06 10:33:57 Page View：139

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： HPV cancer vaccine study demonstrates efficacy
Next article： 23andMe had bad news about my health. I wish a person had delivered it

explore

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

ScientistFengZhang,right,isinterviewedbyreporterMeganMolteniatSTAT'sBreakthroughSummitEast.STATWhent

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

U.K. officials, researchers try to ease path for bespoke genetic treatments

AdobeLONDON—Widespreadgenetictestingaswellasthedevelopmentofcutting-edge,customizedgenetictherapiesh

WSS

Wikipedia

Wikipedia

knowledge

explore

U.K. officials, researchers try to ease path for bespoke genetic treatments